Effectiveness of Candesartan combined with steroid pulse therapy and tonsillectomy on clinical remission in Immunoglobulin A (IgA) nephropathy
Phase 2
Recruiting
- Conditions
- IgA nephropathyRenal and Urogenital - Kidney disease
- Registration Number
- ACTRN12610000516088
- Lead Sponsor
- Cardiovascular medicine, nephrology and neurology, University of the Ryukyus
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
1.Histologically proven Ig A nephropathy patients
2.Serum creatinine levels is < 1.5 mg/dl
3.Urinary protein excretion is equal to and more than 0.5g/g creatinine and
urinary red blood cell counts is equal to and more than 10/high power field
4.Histologically proven focal active lesion
Exclusion Criteria
1.Recent onset of cardiovascular disease 2.Severe hypertension (high systolic blood pressure >200mmHg or high diastolic blood pressure >100mmHg
3.Diabetes mellitus
4.Patient on angiotensin converting enzyme inhibitors (ACEI) or other angiotensin receptor blockades (ARB)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Remission rate of proteinuria and hematuria<br>1) assess morning urine by urine analysis and chemistry<br>2) definition of remission <br> a) proteinuria: urinary protein less than 0.2 g/gCr <br> b) hemeturia : urinary renal blood cell counts less than 5/ high power field[6 months, 12 months and 24 months following randomisation];Reduction rate of proteinuria and hematuria, which is assess morning urine by urine analysis and chemistry[6 months, 12 months and 24 months following randomisation]
- Secondary Outcome Measures
Name Time Method Change in kidney function, which is assessed by estimated glomerular filtration rate (eGFR)[6 months, 12 months and 24 months following randomisation]